Renal Denervation in Hypertension and Chronic Heart Failure

Area of Science:

• Cardiovascular medicine
• Interventional cardiology
• Nephrology

Background:

• Sympathetic nervous system overactivity contributes to cardiovascular and metabolic diseases.
• Patient adherence to pharmacologic therapy is a significant challenge for long-term blood pressure control.
• Renal denervation (RDN) targets renal sympathetic nerves to modulate sympathetic activity.

Purpose of the Study:

• To review the physiological basis of RDN.
• To summarize current evidence on RDN's effectiveness in hypertension and other conditions.
• To discuss RDN technologies and future directions, including multiorgan denervation.

Main Methods:

• Review of existing literature and clinical trial data on RDN.
• Analysis of physiological mechanisms underlying RDN's effects.
• Evaluation of current and emerging RDN technologies.

Main Results:

• RDN has shown consistent efficacy in recent sham-controlled trials for hypertension.
• RDN is now included in European guidelines for select hypertension patients.
• Evidence suggests a potential role for RDN in chronic heart failure and other sympathetic hyperactivity conditions.

Conclusions:

• RDN is an effective treatment option for resistant hypertension, independent of medication adherence.
• RDN is increasingly recognized and endorsed by major cardiovascular and hypertension societies.
• Future research is exploring broader applications of denervation beyond the kidneys for enhanced sympathetic modulation.